Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

Hossein Borghaei, DO
Published: Monday, Oct 24, 2016


Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab
(Keytruda) in second-line non–small cell lung cancer (NSCLC).
 
There is no head-to-head comparison of 1 agent versus the other, said Borghaei, so all oncologists have to go on are the clinical data from separate clinical trials. It is always difficult to do cross-trial comparisons, he said.
 
Scheduling is a factor in decision making, as nivolumab is given every 2 weeks versus pembrolizumab which is given every three weeks.
 
From a clinical decision-making process, most patients who are now in second-line, as long as they have reasonable performance status and can withstand any potential toxicity that could arise, would be candidates for treatment with either of these agents, said Borghaei.

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab
(Keytruda) in second-line non–small cell lung cancer (NSCLC).
 
There is no head-to-head comparison of 1 agent versus the other, said Borghaei, so all oncologists have to go on are the clinical data from separate clinical trials. It is always difficult to do cross-trial comparisons, he said.
 
Scheduling is a factor in decision making, as nivolumab is given every 2 weeks versus pembrolizumab which is given every three weeks.
 
From a clinical decision-making process, most patients who are now in second-line, as long as they have reasonable performance status and can withstand any potential toxicity that could arise, would be candidates for treatment with either of these agents, said Borghaei.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x